Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient
Abstract Pulmonary embolism has a high frequency in COVID‐19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID‐19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary...
Saved in:
| Main Author: | Yucel Colkesen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.7116 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of half-dose alteplase and LMWH in intermediate-high risk pulmonary embolism: a single-center observational study
by: Ömer Selim Selim Unat, et al.
Published: (2025-07-01) -
The Aftermath of Pulmonary Embolism: Are Residual Thrombi Clinically Significant?
by: Irina Pocienė, et al.
Published: (2025-05-01) -
Low-dose and low-contrast computed tomography pulmonary angiography in pediatric with pulmonary embolism: a prospective study
by: Kaihua Yang, et al.
Published: (2025-04-01) -
Assessing the severity of acute pulmonary embolism: A review of epidemiological, clinical, biological, and CT angiography parameters
by: Jean-Pierre Tshungu Muteleshi, et al.
Published: (2025-07-01) -
Prognostic accuracy of Whole Lung Perfusion Blood Volume as a predictor of 28-day Mortality in Acute Pulmonary Thromboembolism – A prospective study
by: N Krishna Reddy, et al.
Published: (2025-01-01)